Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 8% – Here’s Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) was up 8% on Wednesday . The stock traded as high as $24.41 and last traded at $24.08. Approximately 93,002 shares traded hands during trading, a decline of 63% from the average daily volume of 251,486 shares. The stock had previously closed at $22.29.

Analysts Set New Price Targets

DNTH has been the subject of several research reports. Oppenheimer increased their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research report on Monday, November 11th. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Finally, TD Cowen started coverage on shares of Dianthus Therapeutics in a research note on Friday, December 20th. They set a “buy” rating for the company. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $46.43.

Dianthus Therapeutics Stock Performance

The firm’s 50 day moving average is $23.06 and its 200 day moving average is $25.88. The stock has a market cap of $733.16 million, a P/E ratio of -9.91 and a beta of 1.72.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The business had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.07 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. As a group, analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Jane Street Group LLC purchased a new stake in Dianthus Therapeutics during the 3rd quarter worth approximately $556,000. Barclays PLC grew its holdings in shares of Dianthus Therapeutics by 390.5% during the third quarter. Barclays PLC now owns 41,684 shares of the company’s stock valued at $1,141,000 after buying an additional 33,185 shares during the last quarter. HighVista Strategies LLC acquired a new position in shares of Dianthus Therapeutics in the third quarter valued at about $542,000. State Street Corp lifted its stake in Dianthus Therapeutics by 101.4% during the 3rd quarter. State Street Corp now owns 821,131 shares of the company’s stock valued at $22,483,000 after acquiring an additional 413,425 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Dianthus Therapeutics by 142.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock valued at $4,543,000 after acquiring an additional 97,362 shares during the last quarter. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.